Diabetic Product Development Leads to Name Change: Sernova Corp.

Kelowna, B.C. - Pheromone Sciences Corp.
is
pleased to announce it has changed its name to
Sernova
Corp. ("Sernova"). The company's new stock
symbol is
SVA.

"The new name fits better with projects such as
our
current development of a potential breakthrough
treatment
for diabetes," said Chairman Dr. William
Cochrane. "We
wanted a new name to help make it clear to
investors that
our focus is no longer centred around
pheromones, but
can include all kinds of biotechnology
developments."

Shareholders approved the name change at the
Company's annual general meeting held on
August 18th
2006 and elected 5 directors to the Board: Dr.
William
Cochrane (Chair), Charles Allard, Justin
Leushner,
Devinder Randhawa and Dr. Eldon Smith.

Sernova Corp. is a biotechnology research and
development company focused on
commercializing
medical technologies.

This news release may contain forward-looking
statements. Forward-looking statements address
future
events and conditions and therefore involve
inherent risks
and uncertainties. Actual results may differ
materially from
those currently anticipated in such statements.

Press ReleaseCommuniqué de presse
-
April 28, 200928 April, 2009

New Strategic Plan

At the Annual General Meeting of Shareholders
held
today, the Sernova Board of Directors issued its
report on
the internal review of the Corporation's research
and
development, financing and partnering activities
and
strategies that had been conducted over the last
three
months by Mr. Jeffrey Bacha, an independent
Director of
the Corporation. Based on the analysis of the
Corporation's scientific progress to date,
regulatory
requirements, and financial and human
resources, the
Board of Directors has approved Mr. Bacha's
recommended strategic plan.

Sernova's immediate priority will be to seek
scientific
collaborations with key international transplant
centres
that currently offer islet transplantation (known
as the
Edmonton Protocol) to patients suffering from
Type 1
diabetes. Sernova strongly believes that its
proprietary
Sertolin(tm) technology, which utilizes co-
transplantation of
porcine islets and Sertoli cells in a unique
transplantation
device, offers a quantum leap forward over the
Edmonton
Protocol, the current standard of care. The
limitations of
the Edmonton Protocol are well understood: very
small
source of donated human islets, potential
damage to the
patient's liver, significant loss of islets following
transplantation, severe immune and
inflammatory
responses to the transplanted islets, and the
permanent
need for the patient to take toxic and expensive
anti-
rejection drugs. The Sertolin(tm) treatment would
potentially overcome all of the Edmonton
Protocol
limitations in a simpler, less invasive, safer and
less
expensive way, since it is based on the
availability of a
large supply of porcine islets and sertoli cells
from
controlled herds, reduced loss of islets following
transplantation, no minimal immune or
inflammatory
responses, and no need for any antirejection
drugs.

Sernova has already initiated discussions with
several key
transplantation centres in the United States with
a view to
establishing scientific collaborations to
demonstrate proof
of concept and commercialize Sertolin(tm). Mr.
Bacha
stated: "By working together with leading
transplant
centres, we can achieve far more in a shorter
period of
time, and ensure the highest quality studies that
will meet
the standards of the FDA and the international
scientific
community."

Sernova is also aggressively seeking
government and
private grants to fund key projects within the
overall
Sertolin(tm) development plan. Until further
funding and/or
scientific collaborations are secured, the
Corporation has
significantly reduced its overhead and operating
expenses.

The Board of Directors also announces the
appointment of
Dr. Philip Toleikis as the President and CEO of
the
Corporation. Dr. Toleikis is a seasoned and
experienced
biotechnology executive, with over 20 years of
research,
intellectual property, management and business
experience in the pharmacology and
biotechnology
sectors. His most recent position was as Vice
President,
R&D Pharmacology and Drug Screening, for
Angiotech
Pharmaceuticals, Inc. of Vancouver, British
Columbia,
where he built a major scientific and information
technology team that included senior scientists,
research
scientists and technicians. Dr. Toleikis' major
achievements at Angiotech included successful
completion of Phase II European Clinical Trials,
chairing
the Joint Research Committee, in-licensing and
out-
licensing of technologies, and management of
key patents
and patent applications. Dr. Toleikis is the author
of
multiple issued patents and over 110 patent
applications.
His research training and experience includes
biochemical
pharmacology, diabetes, oncology, inflammatory
diseases
(psoriasis, multiple sclerosis, surgical adhesions,
Alzheimer's disease and rheumatoid arthritis),
osteoarthritis, neurological diseases and
cardiovascular
conditions including ischemic heart disease,
cardiomyopathy, hypertension and aneurysms.
Dr.
Toleikis will be presenting on the Corporation's
behalf at
the BioFinance Conference in Toronto on
Wednesday,
April 29, 2009.

Dr. George Adams, Chairman of the Board of
Directors,
welcomed Dr. Toleikis, stating "Sernova is
privileged to
now be led by such a distinguished scientist and
executive. We are fully confident that Dr. Toleikis
will drive
our technology through the worldwide regulatory
process
and into commercialization. The treatment of
insulin-
dependent diabetes will be just the first
commercial
application of our platform technology. On behalf
of the
Board of Directors and our shareholders, I
welcome Dr.
Toleikis to the Sernova family."

Sernova also announces that it will be seeking
the
approval of the TSX Venture Exchange for a
private
placement of up to 14 million shares at a price of
$0.03
per common share, for aggregate consideration
of
$420,000. A commission of 10%, along with a
10% agents
warrant to purchase common shares at $0.05
per
common share, will be paid.

The Corporation also announces the granting of
incentive
stock options to an officer to purchase up to
700,000
common shares at $0.10 per share for a period
of 5 years
expiring April 28, 2014.

About Sernova
Sernova Corp. is a Canadian-based, health-
sciences
company focused on commercializing medical
technologies. Sernova is currently developing a
platform
technology for a number of serious disease
indications,
starting with a novel treatment for insulin-
dependent
diabetes, using its patented Sertolin cell
technology.
According to the American Diabetes Association
approximately 9 million Americans require insulin
injections and it is the sixth leading cause of
death in the
United States. One out of every 8 dollars spent
on health
care in the United States is spent on treating
diabetes and
its complications. Worldwide expenditures on
insulin alone
are estimated to be $15 billion annually and
growing.

This news release may contain forward-looking
statements. Forward-looking statements address
future
events and conditions and therefore involve
inherent risks
and uncertainties. Actual results may differ
materially from
those currently anticipated in such statements.

Press ReleaseCommuniqué de presse
-
July 12, 201012 July, 2010

LONDON, ONTARIO--(Marketwire -- July 12,
2010) -
Sernova Corp. (TSX VENTURE:SVA) is pleased
to report
positive results from a long-term study
evaluating the
safety and efficacy of the Cell Pouch System(TM)
in a pre-
clinical model of diabetes.

Detailed data will be presented at the 23rd
International
Conference of the Transplant Society,
Vancouver, British
Columbia, Canada, August 15th-19th in a
presentation
entitled, "A novel Cell Pouch(TM), an alternative
to
intrahepatic islet transplantation."

Dr. Philip Toleikis, Sernova's President & CEO,
noted "Our
Cell Pouch System(TM) is a proprietary medical
device
implanted under the skin rapidly forming into a
tissue-
engineered, organ-like structure that provides a
natural
environment for the survival and function of
therapeutic
cells. These long-term results represent a
significant
achievement as a possible alternative to the
current
practice of injecting islets directly into the portal
vein of the
liver."

"Our data are profound because they suggest
the
potential to reduce side-effects associated with
the current
standard of care and achieve glucose control
with
significantly fewer islets than normally required,"
said
Toleikis.

The following summarizes important new
findings reported
today:
Long-term insulin independence was
successfully
achieved with significantly fewer islets than the
current
standard of care, requiring only about 10% of
insulin-
producing islets normally used for the Edmonton
Protocol.
Animals in the study achieved long-term glucose
normalization throughout the course of the study.
Standard laboratory tests demonstrated
transplanted islets
produced insulin and responded similarly to non-
diabetic
animals to provide control of glucose.
No adverse events related to the Cell Pouch
System(TM)
occurred during the study.
About the Study

The Cell Pouch System(TM) was implanted in
pigs which
were then made diabetic through removing the
pancreas
and chemical induction. The animal's own islets
(Autograft)
isolated from the pancreas were transplanted
into the
device. Standard measures of efficacy including
fasting
and non-fasting glucose levels, glucose
tolerance tests
(IVGTT), and C-peptide were taken up to 72 days
post-
transplant. At the end of the study period, the
device
containing the islets was removed and the
animals
returned to a diabetic state.

Following transplantation, a substantial number
of study
animals maintained glucose levels within the
normal
range, showed glucose tolerance tests (IVGTT)
similar to
non-diabetic animals and were C-peptide
positive, an
important confirmation of insulin-producing islet
function.
Microscopic fluorescence analysis of the device
revealed
both microvessels and insulin associated with
islets.

Upon removal of the Cell Pouch System(TM)
containing
islets, fasting glucose levels returned to the
diabetic range
and animals required daily insulin injections to
maintain
normal glucose levels. The animals return to the
diabetic
state was further confirmed by IVGTT and C-
peptide
analysis.

From a safety perspective, no adverse events
occurred
related to the Cell Pouch(TM) throughout the
study
following implantation of over 40 devices for up
to 5
months. The devices were well-incorporated with
collagen
at all time points and yet were not visible under
the skin,
an important consideration for patients.

Dr. David White, Chair of Sernova's Scientific
Advisory
Board stated, "I am particularly enthusiastic
about these
results and the potential clinical relevance to
patients
suffering from diabetes. These new data suggest
that the
Cell Pouch System(TM) represent a possible
clinically
relevant alternative to injection of islets into the
portal vein
of the liver and may reduce the side effects of
transplantation including the instant blood-
mediated
reaction (IBMR). The indication that our device
achieves
glucose control with a reduction in the number of
islets
normally required is also of profound clinical
importance
as it may increase the availability of life-changing
islet
transplantation to many diabetic patients."

Sernova believes that the Cell Pouch
System(TM) has the
potential for a wide range of uses in cell therapy
including
the treatment of diabetes, haemophilia, and
other chronic
debilitating diseases. Based on these
encouraging results,
the Company is taking steps towards clinical
evaluation of
its Cell Pouch System(TM).

According to the American Diabetes Association
approximately 9 million Americans require insulin
injections and it is the sixth leading cause of
death in the
United States. One out of every eight dollars
spent on
health care in the United States is spent on
treating
diabetes and its complications. Worldwide
expenditures on
insulin alone are estimated to be $15 billion
annually and
growing.

About Sernova

Sernova Corp. is a Canadian-based health
sciences
company focused on product development and
commercialization of innovative proprietary
platform
medical technologies in the cell therapy arena
such as the
Cell Pouch System(TM) to provide a safe and
efficacious
environment for therapeutic cells and
Sertolin(TM), a
technology which, when combined with cell
therapy, may
protect therapeutic cells without the need for
patients to
take anti-rejection drugs.

Neither the TSX Venture Exchange nor its
Regulation
Services Provider (as that term is defined in the
policies of
the TSX Venture Exchange) accepts
responsibility for the
adequacy or accuracy of this release.

The securities offered have not been, and will
not be,
registered under the United States Securities Act
of 1933,
as amended, and may not be offered or sold in
the United
States absent registration or any applicable
exemption
from the registration requirement of such Act.
This press
release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be
any sale of
these securities in any jurisdiction in which such
offer,
solicitation or sale would be unlawful.

This news release contains forward-looking
information,
which involves known and unknown risks,
uncertainties
and other factors that may cause actual events
to differ
materially from current expectation. Important
factors -
including availability of funds, the results of
financing
efforts, the results of research and product
development
activities - that could cause actual results to differ
materially from Sernova's expectations are
disclosed in
Sernova's documents filed from time to time on
SEDAR
(see www.sedar.com). Readers are cautioned
not to place
undue reliance on these forward-looking
statements,
which speak only as of the date of this press
release. The
company disclaims any intention or obligation,
except to
the extent required by law, to update or revise
any
forward-looking statements, whether as a result
of new
information, future events or otherwise.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
March 03, 20113 March, 2011

LONDON, ONTARIO--(Marketwire - March 3,
2011) -
Sernova Corp. (TSX VENTURE:SVA) is pleased
to
announce the Company will present results of
preclinical
studies with its Cell Pouch System(TM), at the
Canadian
Society of Transplantation 2011 Annual Scientific
Conference at Mt-Tremblant, Quebec, Canada
held March
2-5.

The conference brings together eminent
scientists and
clinicians in the cell and organ transplantation
field from
across Canada and around the world. Sernova
will be
making three poster presentations entitled:

"The establishment of a stringent large animal
model of
insulin-dependent diabetes"

"A subcutaneous Cell Pouch(TM) as an
alternative to
intraportal infusion of islets of Langerhans to
restore
carbohydrate control in the diabetic recipient,"
and

"The conference provides a venue to discuss the
attributes of Sernova's novel Cell Pouch
System(TM) as
an alternate site for insulin-producing islet
transplantation
and its potential for additional cellular therapies
with
leaders from the medical transplantation
community,"
stated Delfina Siroen, Sernova's Research and
Development Head.

The Cell Pouch System(TM) is a proprietary
medical
device which may offer a revolutionary
improvement over
the current practice of injecting therapeutic cells
into blood
vessels. Based on previous pre-clinical research,
the Cell
Pouch System(TM) becomes a vascularised
organ-like
endocrine structure when placed in the body,
providing
the microcirculation thought to be essential to
early
function and long-term survival of therapeutic
cells.
Sernova has conducted efficacy studies in small
and large
animal models of diabetes and shown the device
with
insulin-producing islets to control blood glucose
levels
long-term without the need for daily insulin
injections.
Sernova believes the Cell Pouch System(TM)
has the
potential for a wide range of uses in cell therapy
including
the treatment of diabetes, haemophilia, spinal
cord injury,
Parkinson's disease and other chronic
debilitating
diseases.

According to the American Diabetes Association
approximately 9 million Americans require insulin
injections and it is the sixth leading cause of
death in the
United States. One out of every 8 dollars spent
on health
care in the United States is spent on treating
diabetes and
its complications. Worldwide expenditures on
insulin alone
are estimated to be $15 billion annually and
growing.

About Sernova

Sernova Corp. is a Canadian-based health
sciences
company focused on product development and
commercialization of innovative proprietary
platform
medical technologies in the cell therapy arena
such as the
Cell Pouch System(TM) to provide a safe and
efficacious
environment for therapeutic cells and
Sertolin(TM), a
technology which, when combined with cell
therapy, may
protect therapeutic cells without the need for
patients to
take anti-rejection drugs.

Neither the TSX Venture Exchange nor its
Regulation
Services Provider (as that term is defined in the
policies of
the TSX Venture Exchange) accepts
responsibility for the
adequacy or accuracy of this release.

This news release contains forward-looking
information,
which involves known and unknown risks,
uncertainties
and other factors that may cause actual events
to differ
materially from current expectation. Important
factors -
including availability of funds, the results of
financing
efforts, the results of research and product
development
activities -- that could cause actual results to
differ
materially from Sernova's expectations are
disclosed in
Sernova's documents filed from time to time on
SEDAR
(see www.sedar.com). Readers are cautioned
not to place
undue reliance on these forward-looking
statements,
which speak only as of the date of this press
release. The
company disclaims any intention or obligation,
except to
the extent required by law, to update or revise
any
forward-looking statements, whether as a result
of new
information, future events or otherwise.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
October 25, 201125 October, 2011

LONDON, ONTARIO - (Marketwire - October 25,
2011) -
Sernova Corp. (TSX-V: SVA), is pleased to
announce it
has entered into a collaboration with The Clinical
Islet
Transplant Program at the University of Alberta
Hospital.

The Program is headed by Dr. James Shapiro,
MD, Ph.D.
FRCS (Eng) FRCSC, the leader of the team that
developed
the Edmonton Protocol, the current standard of
care for
islet transplantation. In September 2010,
following review
of Sernova's preclinical data, Dr. Shapiro joined
the
Corporation's Scientific Advisory Board.

"Dr. Shapiro's contributions to date position us to
enter
into this important collaboration which is targeted
to
expand access to islet transplantation for the
treatment of
diabetes to a much wider base of patients using
Sernova's
Cell Pouch(tm)," said Dr. Philip Toleikis, Ph.D.,
President
and CEO of Sernova.

The current procedure for islet transplantation to
treat
diabetes, commonly known as the "Edmonton
Protocol"
involves transplanting islets directly into a blood
vessel
(portal vein) of the liver. The Cell Pouch(tm) is
expected to
solve a number of issues arising from portal vein
delivery.
For example, the Cell Pouch(tm) provides a
natural setting
where blood vessels grow adjacent to the islets
rather
than being bathed in blood which can result in
the death of
up to 75% of the islets through an instant blood
mediated
inflammatory response (IBMIR). Use of the Cell
Pouch(tm)
would eliminate portal vein hypertension and
thrombosis
associated with portal vein islet delivery and
potentially
reduce the cost of the procedure as the
catheterization
laboratory is not required for implantation of the
Cell
Pouch(tm) or islet transplantation. Importantly,
preclinical
studies of the Cell Pouch(tm) have consistently
shown
excellent safety and efficacy profiles with
significantly
fewer islets than for portal vein delivery, which
could
increase the number of recipients treated with
the current
donor pool. Furthermore, implantation of the Cell
Pouch(tm) just under the skin allows for imaging
of the
islets and microvessels and for local
immunoprotection of
therapeutic cells.

Sernova's Cell Pouch(tm) is a scalable medical
device
providing a natural "organ-like" environment for
therapeutic cells. Once implanted under the skin,
the Cell
Pouch(tm) develops pancreas-like function when
infused
with islets, controlling blood sugar levels as
shown by
published preclinical data which also suggests
that the
natural environment promotes cell survival
reducing the
number of islets required for therapy.

Sernova is currently pursuing upcoming human
testing of
the Cell Pouch(tm) based on the strong
preclinical safety
and efficacy data generated to date.

This collaboration will further seek to position the
Cell
Pouch(tm) through next generation
improvements to the
Edmonton Protocol to expand access to cell
transplant to a
much wider patient population. The collaboration
will
include work related to:
Assessment of islet protective agents that could
further
reduce the islet mass required for each
transplant using
the Cell Pouch(tm)

Assessment of locally administered anti-rejection
strategies within the Cell Pouch(tm) with the goal
of
reducing or eliminating systemic antirejection
regimens

Assessment of a proprietary, ethically derived
insulin-
producing stem cell technology within the Cell
Pouch(tm)
as an enabling technology which could
significantly
expand the number of patients treated

Development of high resolution imaging systems
to enable
physicians to better assess and optimize long-
term islet
function
A video describing the Edmonton Protocol and
the
collaboration of Sernova with Dr. Shapiro may
be viewed
on Sernova's website at www.sernova.com

"The safety and efficacy of the Cell Pouch(tm) in
preclinical
studies is impressive. We are excited to be
working with
Sernova in both preparing for its upcoming
clinical trial and
in this collaboration. We are hopeful that
Sernova's Cell
Pouch(tm) will significantly increase the number
of diabetic
patients that can be treated with islet
transplantation," said
Dr. Shapiro, Director of the Clinical Islet
Transplant
Program, at the University of Alberta and
member of
Sernova's Scientific Advisory Board.

About Sernova

Sernova Corp. is a Canadian-based health
sciences
company focused on product development and
commercialization of innovative proprietary
platform
medical technologies in the cell therapy arena
such as the
Cell Pouch System(TM) to provide a safe and
efficacious
environment for therapeutic cells and
Sertolin(TM), a
technology which, when combined with cell
therapy, may
protect therapeutic cells without the need for
patients to
take anti-rejection drugs.

Neither the TSX Venture Exchange nor its
Regulation
Services Provider (as that term is defined in the
policies of
the TSX Venture Exchange) accepts
responsibility for the
adequacy or accuracy of this release.

The securities offered have not been, and will
not be,
registered under the United States Securities Act
of 1933,
as amended, and may not be offered or sold in
the United
States absent registration or any applicable
exemption
from the registration requirement of such Act.
This press
release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be
any sale of
these securities in any jurisdiction in which such
offer,
solicitation or sale would be unlawful.

This news release contains forward-looking
information,
which involves known and unknown risks,
uncertainties
and other factors that may cause actual events
to differ
materially from current expectation. Important
factors -
including availability of funds, the results of
financing
efforts, the results of research and product
development
activities - that could cause actual results to differ
materially from Sernova's expectations are
disclosed in
Sernova's documents filed from time to time on
SEDAR
(see www.sedar.com). Readers are cautioned
not to place
undue reliance on these forward-looking
statements,
which speak only as of the date of this press
release. The
company disclaims any intention or obligation,
except to
the extent required by law, to update or revise
any
forward-looking statements, whether as a result
of new
information, future events or otherwise.

LONDON, ONTARIO--(Marketwire - May 2,
2012) -
Sernova Corp. ("Sernova" or the "Company")
(TSX
VENTURE: SVA - News) today announced it
received
Health Canada Approval to conduct a human
clinical trial
assessing both the safety and efficacy of
Sernova's Cell
Pouch(TM) with transplanted insulin-producing
islets in
patients with insulin-dependent diabetes. The
study will be
conducted in collaboration with Dr. James
Shapiro at the
University of Alberta Health Science Centre in
Edmonton.

"Sernova's compelling pre-clinical results
provide
optimism that the Cell Pouch(TM) has the
potential to
change the standard of care of patients with
diabetes
receiving islet transplantation," said Dr. James
Shapiro,
principal investigator of the study. "I am excited
to begin
enrolment of patients in this ground breaking
clinical study
to evaluate the Cell Pouch(TM) in humans."

The study, entitled "A Phase I/II Study of the
Safety and
Efficacy of Sernova's Cell Pouch(TM) for
Therapeutic Islet
Transplantation," is an open label, non-
randomized,
single-arm, Phase I/II safety and efficacy study
of up to 20
patients with insulin-dependent diabetes
undergoing
allograft pancreatic islet transplantation.

In this study, patients who have met the
enrolment criteria
and provided informed consent will be implanted
with the
Cell Pouch(TM) approximately 2-12 weeks prior
to
transplantation of donor human islets. To prevent
islet
graft rejection, patients will be treated with the
standard
immunosuppressive regimen.

The primary endpoint of the study is to assess
the safety
of the Sernova Cell Pouch(TM) in adult
participants with
Type-1 diabetes receiving islet transplantation
for the first
time. This endpoint will be assessed just prior to
islet
transplantation and one month thereafter.

The secondary endpoint of the study is to
determine the
proportion of subjects implanted with the Cell
Pouch(TM)
and transplanted with islets who achieve and
maintain
insulin independence as measured three months
post-final
islet transplantation.

In addition, the study will provide preliminary
data on the
efficacy of the Cell Pouch(TM) to maintain
adequate
immunological protection against both allo- and
autoimmunity of islet transplant recipients.

Following assessment of primary and secondary
endpoints, patients will be followed for a
minimum of three
years to assess long-term safety and efficacy of
the Cell
Pouch(TM). It should also be noted that the study
allows
for interim analysis of the data at various study
time
points.

"The initiation of this study marks a significant
milestone
for Sernova, and is the result of years of hard
work and
dedication from our company's staff and
collaborators,"
said Dr. Philip Toleikis, President and CEO of
Sernova
Corp. "We have developed the subcutaneous
Cell
Pouch(TM) for Sernova's first clinical application,
insulin-
dependent diabetes, as an alternative site for
islet
transplantation that may allow for safer, more
efficient
engraftment of islets and potential improved
long-term
insulin independence using a marginal islet
mass. We are
pleased to have Dr. Shapiro and his team
conduct this
study at this world class institute for islet
transplantation."

The Cell Pouch(TM) is a proprietary medical
device that,
once implanted subcutaneously, incorporates
with tissue
and microvessels. It has been shown in multiple
preclinical
studies to provide a safe environment for
transplantation,
as well as long-term survival and efficacy of
therapeutic
cells. Sernova's goals for the diabetes indication
include
making the Cell Pouch(TM) available to a wider
group of
patients than currently possible with intraportal
delivery of
islets. Sernova also plans to make the Cell
Pouch(TM)
available as a natural, improved site for non-
primary-
derived, insulin-secreting cells for long-term
function to
enable large numbers of patients with insulin-
dependent
diabetes to be treated without limitation to
availability of
cells.

About Sernova

Sernova Corp. is a clinical stage health-sciences
company
focused on commercializing medical
technologies.
Sernova is currently developing a platform
technology for
a number of serious disease indications, starting
with a
novel treatment for insulin-dependent diabetes,
using the
novel Cell Pouch System(TM) for transplantation
and long-
term survival of therapeutic cells and its patented
Sertolin(TM) cell technology which can provide
an
immune-protected local environment for
therapeutic cells.

Forward Looking Information This release may
contain
forward-looking statements. Forward-looking
statements
are statements that are not historical facts and
are
generally, but not always, identified by the words
"expects", "plans", "anticipates", "believes",
"intends",
"estimates", "projects", "potential" and similar
expressions, or that events or conditions "will",
"would",
"may", "could" or "should" occur. Although
Sernova
believes the expectations expressed in such
forward-
looking statements are based on reasonable
assumptions,
such statements are not guarantees of future
performance
and actual results may differ materially from
those in
forward looking statements. Forward-looking
statements
are based on the beliefs, estimates and opinions
of
Sernova's management on the date such
statements
were made. Sernova expressly disclaims any
intention or
obligation to update or revise any forward-
looking
statements whether as a result of new
information, future
events or otherwise.

Neither the TSX Venture Exchange nor its
Regulation
Services Provider (as that term is defined in the
policies of
the TSX Venture Exchange) accepts
responsibility for the
adequacy or accuracy of this release.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
August 15, 201215 August, 2012

World First - Islet Transplant Into Man Using Sernova's Cell Pouch™ For Treatment Of Diabetes

LONDON, ONTARIO and EDMONTON,
ALBERTA
(Marketwire -- August 16, 2012) -- Sernova
Corp.
("Sernova" or the "Company") (TSX VENTURE:
SVA -
News) and the University of Alberta today
announced the
treatment of the first patient with insulin-
producing islets
transplanted into Sernova's Cell Pouch(TM) in a
Phase I/II
clinical study to treat Type-1 diabetes led by Dr.
James
Shapiro, Professor of Surgery and Medicine,
University of
Alberta and Director, Clinical Islet Transplant
Program.
Sernova will host a conference call at 9 a.m.
EDT, today,
Aug. 16, 2012, to discuss the company's clinical
and
business developments.

"The Sernova Cell Pouch(TM) implantation and
transplantation processes are simple, rapid
minimally
invasive procedures, conducted on an outpatient
basis
under local anesthesia," said Dr. Shapiro. "This
offers
substantial potential benefit over the Edmonton
protocol
and the ease of use provides an opportunity for
the Cell
Pouch(TM) to become the standard of care for
people with
diabetes if it proves to be effective in these initial
trials."

The objectives of the human clinical trial are to
assess the
safety and efficacy of the Cell Pouch(TM) with
transplanted islets in up to 20 patients with Type-
1
diabetes. The study is sponsored by Sernova
Corp and
the University of Alberta. In the study, patients
who have
met the enrolment criteria and provided informed
consent
are implanted with the Cell Pouch(TM) prior to
transplantation of donor human islets. To prevent
islet
graft rejection, patients in this study are treated
with the
best in class standard of care
immunosuppression
protocol. Interim analysis of the data from this
clinical
study is expected during H1, 2013. Further
information on
the trial may be found at www.clinicaltrials.gov
(Identifier:
NCT01652911).

"The Cell Pouch(TM) is a breakthrough
technology which
has the potential to significantly improve the lives
of
people living with chronic diseases such as
diabetes," said
Philip Toleikis, Ph.D., President and CEO of
Sernova Corp.
"Supported by Sernova's strong preclinical
results, the
treatment of patients in this clinical trial of the Cell
Pouch(TM) further advances our vision for the
future of
providing millions of diabetic patients with the
Cell
Pouch(TM), and an unlimited source of insulin-
producing
cells protected with a local anti-rejection
technology."

Conference Call

The conference call to discuss Sernova's clinical
and
business developments may be accessed by
dialing 866-
532-1852 for domestic callers and +443-842-
7644 for
international callers. Please specify to the
operator that
you would like to join the "Sernova conference
call" or
"conference ID: 21155379."

About The Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary medical
device that,
following subcutaneous implantation,
incorporates with
tissue and microvessels forming a natural
environment for
transplantation of therapeutic cells. Multiple
preclinical
studies demonstrated the Cell Pouch(TM) to
provide a safe
environment for transplantation, as well as long-
term
efficacy of therapeutic cells. Sernova's goals for
the Cell
Pouch(TM) for diabetes include providing a safe
and
natural site for islets to significantly increase the
number of
patients currently treated with intraportal delivery
of donor
islets and to provide a safe environment for
virtually
unlimited available sources of insulin-secreting
cells such
as insulin-producing stem cells and xenogeneic
cells. This
vision combined with local anti-rejection
protection of the
cells could enable millions of patients with
insulin-
dependent diabetes to be treated without
limitation to
availability of cells.

About Sernova

Sernova Corp. is a clinical stage health-sciences
company
focused on commercializing medical
technologies.
Sernova is currently developing a platform
technology for
a number of serious disease indications, starting
with a
novel treatment for insulin-dependent diabetes,
using the
novel Cell Pouch System(TM) for transplantation
and long-
term survival of therapeutic cells and its patented
Sertolin(TM) cell technology which can provide
an
immune-protected local environment for
therapeutic cells.

Forward Looking Information This release may
contain
forward-looking statements. Forward-looking
statements
are statements that are not historical facts and
are
generally, but not always, identified by the words
"expects", "plans", "anticipates", "believes",
"intends",
"estimates", "projects", "potential" and similar
expressions, or that events or conditions "will",
"would",
"may", "could" or "should" occur. Although
Sernova
believes the expectations expressed in such
forward-
looking statements are based on reasonable
assumptions,
such statements are not guarantees of future
performance
and actual results may differ materially from
those in
forward looking statements. Forward-looking
statements
are based on the beliefs, estimates and opinions
of
Sernova's management on the date such
statements
were made. Sernova expressly disclaims any
intention or
obligation to update or revise any forward-
looking
statements whether as a result of new
information, future
events or otherwise.

Neither the TSX Venture Exchange nor its
Regulation
Services Provider (as that term is defined in the
policies of
the TSX Venture Exchange) accepts
responsibility for the
adequacy or accuracy of this release.

Sernova and Centre for Commercialization of Regenerative Medicine Partner To Treat Chronic Diseases

February 28, 2013 (TORONTO and LONDON,
ON) -- The
Centre for Commercialization of Regenerative
Medicine
(CCRM) is pleased to announce the addition of
Sernova
Corp. ("Sernova" or the "Company") (TSX
VENTURE: SVA
- News) to its member-based industry
consortium.
Sernova's combination of immuno-protective
technology
and therapeutic cells for the treatment of chronic
diseases
advances CCRM's goal of developing innovative
cell-
based product.

"Sernova's technology for transplanting
therapeutic cells
into an implanted medical device for the
treatment of
diabetes and other chronic diseases goes hand-
in-hand
with our strategy of translating cell-based
medical
discoveries into commercial products and
therapies," says
Dr. Michael May, CEO of CCRM. "Sernova's
expertise in
the area of cell therapy will bring great value to
CCRM's
core development platforms and to other
consortium
members."

CCRM is working with its industry consortium to
address
real-life bottlenecks in cell-based product
pipelines. Its
industry consortium now numbers over 20
members.
These companies represent the key sectors of
the
industry: therapeutics, devices, reagents, and
cells as
tools.

"Becoming a member of CCRM offers the
opportunity for
further validation for our technology and
demonstrates our
company's commitment to the advancement of
our Cell
Pouch System(tm) as an effective, safe, long-
term and
convenient therapeutic option for the treatment
of chronic
diseases," says Dr. Philip Toleikis, President and
CEO of
Sernova Corp. "We will work together with the
other
consortium members to achieve CCRM's
objectives in
treating and managing devastating diseases
such as
diabetes."

CCRM has built three core development
platforms: cell
reprogramming and engineering; cell
manufacturing; and,
biomaterials and devices to carry out projects
commissioned by academia and industry. CCRM
has a
fully resourced, 6,000 square foot development
facility
where all development work takes place.

Please visit www.ccrm.ca/industry-consortium to
see a
complete list of CCRM's members.

About the Centre for Commercialization of
Regenerative
Medicine (CCRM)
CCRM, a Canadian not-for-profit organization
funded by
the Government of Canada's Networks of
Centres of
Excellence program and six academic partners,
supports
the development of technologies that accelerate
the
commercialization of stem cell- and biomaterials-
based
technologies and therapies. A network of
academics,
industry and entrepreneurs, CCRM aims to
translate
scientific discoveries into marketable products for
patients.
CCRM launched in Toronto's Discovery District
on June
14, 2011.

About Sernova
Sernova Corp. is a clinical stage health-sciences
company
focused on commercializing medical
technologies.
Sernova is currently developing a platform
technology for
a number of serious disease indications, starting
with a
novel treatment for insulin-dependent diabetes,
using the
novel Cell Pouch System(TM) for transplantation
and long-
term survival of therapeutic cells and its patented
Sertolin(TM) cell technology, which can provide
an
immune-protected local environment for
therapeutic cells.

Sernova And Medicyte To Collaborate On Cell-Based Therapy To Treat Haemophilia

* Novel Approach to Address Unmet Need for an
Effective Therapy *

LONDON, ONTARIO and HEIDELBERG, GERMANY--
(Marketwire -- September 10, 2013) - Sernova Corp. (TSX-
V: SVA) and Medicyte GmbH, today announced that the
companies have entered into a Material Transfer
Agreement (MTA) to jointly evaluate the use of Medicyte's
upcyte® cells in Sernova's Cell Pouch(TM) for the
treatment of patients with haemophilia A.

The two companies have also entered into a nonbinding
term sheet outlining the general terms of a collaboration
for the pre-clinical and clinical development of the novel
Cell Pouch(TM)/upcyte® combination product for the
treatment of haemophilia A. The parties intend to complete
negotiations of a definitive agreement while initial research
is being carried out under the terms of the MTA.

"The joint development program with Medicyte is further
indication that our Cell Pouch(TM) technology is versatile
and has high potential to be employed for the treatment of
a range of chronic diseases," said Dr. Philip Toleikis,
President and CEO Sernova Corp. "We are in line with our
strategy to expand the testing of the Cell Pouch(TM) in
various indications by collaborating with leading cell-based
therapy companies, such as Medicyte."

Dr. Joris Braspenning, CEO of Medicyte, added, "There is
a great unmet medical need for the treatment of severe
haemophilia A. We believe that Medicyte's upcyte® cells
being sheltered in Sernova's Cell Pouch(TM) represent a
promising combination of technologies to produce
effective levels of Factor VIII, and to prevent excessive
bleeding episodes of patients suffering haemophilia A.
Together with Sernova, we are looking forward to
evaluating the potential of a combined product."

Haemophilia A is the most common form of haemophilia
and results from a deficiency of clotting Factor VIII to a
level of less than 1% of the normal blood concentration.
Haemophiliacs have prolonged bleeding which in areas
such as the brain can be fatal or inside joints can be
permanently debilitating. Approximately 20,000 people in
the United States have the moderate or severe form of
haemophilia A, as well as approximately 2,500 in Canada
and 10,000 in Europe. Though there is no cure for
haemophilia A, it is currently controlled with regular
injections of recombinant clotting Factor VIII. Annual costs
for the treatment of the disease may range from $60,000
to $260,000 per patient for a total cost of between $2-4B
per year in North America and Europe.

Development of a product capable of producing an
effective level of Factor VIII within the Cell Pouch(TM)
environment has the potential to provide haemophilia A
patients with better protection against dangerous episodes
of excessive bleeding and greatly reduce annual therapy
costs.

Continuation of the parties' joint studies beyond the MTA
is subject to negotiation and execution of a definitive
collaboration agreement.

About Medicyte

Medicyte is specialised in the controlled generation and
standardisation of human primary cell products in virtually
unlimited quantities and of highest quality for cell therapy
and cell-based R&D. Medicyte's proprietary technologies
upcyte® and vericyte® enable researchers to expand
human cells from different donors and from multiple
tissues in a standardized procedure, thereby making these
cells for the first time commercially available in high
numbers and consistent quality. Beside their therapeutic
applications, pharmaceutical companies are using
upcyte® and vericyte® products for in vitro assays and
ADMET testing.

About Sernova
Sernova Corp. is a clinical stage health-sciences company
focused on commercializing medical technologies.
Sernova is developing a platform technology based on the
Cell Pouch(TM), Sertolin(TM) and therapeutic cells, for a
number of chronic diseases, including insulin-dependent
diabetes as a first indication and other cell therapies for
diseases such as parathyroid disease, haemophilia, and
Parkinson's disease. Sernova's goals for the Cell
Pouch(TM) for diabetes include increasing the number of
patients currently treated with intraportal delivery of donor
islets and to provide a safe environment for sources of
unlimited insulin-secreting cells such as insulin-producing
stem cells and xenogeneic cells. This vision combined with
local anti-rejection protection of the cells could enable
millions of patients with insulin-dependent diabetes to be
treated without limitation to availability of cells.

Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.

This news release contains forward-looking information,
which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ
materially from current expectation. Important factors -
including availability of funds, the results of financing
efforts, the results of research and product development
activities -- that could cause actual results to differ
materially from Sernova's expectations are disclosed in
Sernova's documents filed from time to time on SEDAR
(see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements,
which speak only as of the date of this press release. The
company disclaims any intention or obligation, except to
the extent required by law, to update or revise any
forward-looking statements, whether as a result of new
information, future events or otherwise.

Sernova’s human clinical trial is designed to assess the safety and efficacy of the Cell Pouch in subjects with unstable diabetes receiving an islet transplant. Interim study results in the first group of patients support that the implanted Cell Pouch, transplanted with insulin-producing islets is showing longer-term safety and biocompatibility with one of the patients beyond the 180 day time point.

Encouraging early results up to 30 days post-islet transplant were presented at the International Pancreas and Islet Transplantation Congress in September, 2013. These results showed after implantation under the skin, the Cell Pouch is safe and biocompatible. Following islet transplantation, the islets living within a natural tissue matrix were supported with a rich supply of blood vessels, similar to the pancreas. Of further importance, the islets were shown to make insulin, somatostatin and glucagon – key hormones in the control of blood sugar levels. The ongoing study is being conducted with Dr. James Shapiro as principal investigator at the University of Alberta Health Sciences Centre in Edmonton, Alberta.

"The fact that the Cell Pouch continues to exhibit both safety and biocompatibility in longer term follow-up is an important milestone in the early clinical testing of this device, and provides encouragement that human islets transplanted within the device may provide the opportunity to change the standard of care of patients with diabetes," said Dr. James Shapiro. “I look forward to the ongoing results of the investigation as the study progresses."

The study, entitled “A Phase I/II Study of the Safety and Efficacy of Sernova's Cell Pouch for Therapeutic Islet Transplantation,” is an open label, non- randomized, Phase I/II safety and efficacy study of up to 20 patients with type 1 diabetes undergoing allograft pancreatic islet transplantation. Patients who have met the enrolment criteria and provided informed consent are implanted with the Cell Pouch approximately 2-24 weeks prior to transplantation of donor human islets. To prevent islet graft rejection, the standard of care immunosuppressive regimen is provided.

The primary endpoint of the study is to assess the safety of the Sernova Cell Pouch in these patients just prior to islet transplantation, following islet transplantation and at various points during follow up. The secondary endpoint of the study, efficacy, is to determine the proportion of subjects implanted with the Cell Pouch and transplanted with islets who achieve and maintain insulin independence. Patient follow up occurs for a minimum of three years to assess long-term safety and efficacy.

“In the second half of 2014, we expect to provide further preliminary safety and efficacy data”, remarked Dr. James Shapiro.

"This interim update by Dr. Shapiro suggests we are making positive strides forward. The Cell Pouch could potentially be a game changer for patients suffering from this debilitating disease. Indeed, this is the result of years of hard work and dedication from our company's staff and collaborators," said Dr. Philip Toleikis, President and CEO of Sernova Corp. "We have developed the subcutaneous Cell Pouch for Sernova's first clinical application, insulin- dependent diabetes, as an alternative site for islet transplantation that may allow for safer, more efficient engraftment of islets and potential improved long-term insulin independence using a marginal islet mass. What adds further credence to the Cell Pouch’s mechanism of action is the application of the Cell Pouch for other clinical indications which Sernova is undertaking”, added Dr. Toleikis."

About the Cell Pouch
The Cell Pouch is a proprietary, scalable, biocompatible medical device, that once implanted subcutaneously, incorporates with the patient’s tissue and microvessels. The Cell Pouch is contract manufactured (ISO13485) to meet international regulatory standards. Sernova’s research has demonstrated that when the Cell Pouch is inserted under the skin, it forms an ideal environment, rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with type 1 diabetes receiving an islet transplant.

It has been shown in multiple preclinical studies to provide a safe environment for transplantation, as well as for the long-term survival and efficacy of therapeutic cells. Sernova's goals for the diabetes indication include making the Cell Pouch available to a wider group of patients than currently possible with intraportal delivery of islets. Sernova also plans to make the Cell Pouch available as a natural, improved site for non-primary-derived, insulin-secreting cells. This may enable long-term treatment in large numbers of patients with insulin-dependent diabetes without limitation to availability of donor-derived cells.

About Sernova
Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required.

About Clinical Islet Transplantation Program
Please view www.islet@ca for more information on the Clinical Islet Transplantation Program at the University of Alberta.
For further information contact:

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

LONDON, ONTARIO (Marketwire – February 12, 2015) - Sernova Corp. (TSX-V: SVA), today announced that the Patent Offices in China, Israel, Singapore and New Zealand have issued Notices of Allowance and issued patents to Sernova for its patent application entitled "Methods and Devices for Cellular Transplantation.”

These patents help protect Sernova’s entire Cell Pouch(TM) system, including the Cell Pouch(TM) itself, as well as the Cell Pouch(TM) combined with therapeutic cells and surgical tools for cell transplantation. These issued patents, in addition to patent rights already granted or actively being pursued in other countries, will provide Sernova with patent protection through 2030.

“Patent applications on Sernova’s technologies are being pursued in multiple countries around the world and we are confident that additional patents will be granted on an international basis,” stated Dr. Philip Toleikis, Sernova’s President and CEO.

"Potential strategic partners, including major pharmaceutical companies place significant value in issued patents,” stated Dr. Philip Toleikis, Sernova’s President and CEO. He continued, “Since 2009, we have been relentless at carrying out our strategy to secure exclusive patent rights on our core technologies, to develop an international footprint for our products.”

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary local immune protection technology.

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
April 22, 201522 April, 2015

Sernova Receives Issued Patent in the United States for its Cell Pouch™ and Therapeutic Cell Transplantation Technologies

Sernova Receives Issued Patent in the United States for its Cell Pouch(TM) and Therapeutic Cell Transplantation Technologies

This patent entitled "Methods and Devices for Cellular Transplantation” includes claims covering implantable polymer devices such as the Cell
Pouch(TM) itself, as well as methods using the same combined with therapeutic cells such as self‐cells, donor cells, stem cells and genetically
modified cells as well as surgical tools for cell transplantation. This new patent provides Sernova with patent protection through 2030. Sernova
currently has over 55 issued patents and patent pending applications worldwide covering its therapeutic cell transplantation and local immune
protection technologies.

The USPTO grants a patent after a vigorous search of the existing technology and a determination that a claimed invention is novel and
nonobvious over that technology. Gaining such patent protection is commercially important because the United States represents one of the
world’s largest markets for Sernova’s various therapeutic products in development.

“Since 2009, we have pursued patent rights around the world for our cell transplantation and local immune protection technologies and we will
continue our rigorous strategy to secure and protect our proprietary technologies,” stated Dr. Philip Toleikis, Sernova’s President and CEO.

Within its patented technological armamentarium, Sernova uses biocompatible polymers to develop unique, highly vascularized subcutaneous
tissue chambers for the placement, survival and long term function of therapeutic cells. Over the past six years, Sernova has demonstrated an
excellent safety profile and efficacy benefit for its technologies in small and large animal models of disease and, more importantly, in humans
with severe diabetes where transplanted therapeutic cells become highly vascularized and able to produce their therapeutic product.

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating
metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic
cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from
immune attack by Sernova’s proprietary local immune protection technology.

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are
generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and
similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations
expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future
performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention
or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

LONDON, ONTARIO – (Marketwire – September 10, 2015) – Sernova Corp.
(TSX-V: SVA) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a license agreement with the University Health Network (UHN) of Toronto, Canada to gain exclusive worldwide rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.

”This agreement provides us with a proprietary source of stem cell derived glucose responsive therapeutic cells. When placed within Sernova’s prevascularized Cell Pouch(TM), and protected locally from immune system attack, we believe that Sernova has the potential to provide a significant break-through in the quality of treatment for the millions of people suffering from insulin-dependent diabetes, said Dr. Philip Toleikis, Sernova’s President and CEO”. “Such individuals could essentially be liberated from their current onerous daily regime of multiple blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life, prevent or reduce abnormal glucose complications, and reduce short term and longer term health care costs.”

The current standard of care for islet transplantation is limited to diabetic patients with severe hypoglycemia unawareness due to both a lack of cadaveric donor islets and a requirement for life-long use of toxic anti-rejection drugs.

“We believe that a virtually unlimited supply of glucose responsive therapeutic cells could be generated from ethically derived stem cells which, if shown to have positive safety and efficacy in clinical trials, could be used to treat millions of patients,” commented Delfina Siroen, Sernova’s head of Research and Development. “The addition of the UHN stem cell technologies moves Sernova one step further toward being able to provide a full solution (device, unlimited cell supply and local immune protection) for cell therapy applications.”

About Diabetes
The worldwide incidence of diabetes is approximately 370 million. Sernova’s potential addressable market which includes Type-1 patients and those Type-2 patients requiring insulin is over 30 million people. Although there is currently no cure for diabetes, blood glucose levels are being controlled with frequent blood glucose testing combined with regular injections of insulin via syringe or insulin pump; however, blood glucose control using this treatment approach can be poor, leading to side effects such as heart, kidney and eye diseases as well as ischemia-induced amputations. According to the Juvenile Diabetes Research Foundation, annual health care costs for the treatment of diabetes and its debilitating side effects are estimated to be over US $245 billion per year in North America (http://jdrf.org/).

About Sernova
Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our expectations of the potential benefits of the license agreement, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Distinguished European consortium awarded approximately $8.5 Million CAD by the European Commission via its Horizon 2020 Program to partner advanced cell based Factor VIII therapy in collaboration with Sernova and its Cell Pouch(TM) device technologies

Source: Sernova Corp

December 21, 2015, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – December 21, 2015) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, announced today that the European Commission’s Horizon 2020 program has awarded a Euro 5.6M ($8.5M CAD) grant to a consortium consisting of Sernova Corp and five European academic and private partners to advance development of a GMP clinical grade Factor VIII releasing therapeutic cell product in combination with Sernova’s Cell Pouch(TM) for the treatment of severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream.

The current market for factor VIII is US$5.0B/year, with a cost of up to US$260,000 per patient each year. Current standard of care involves regular infusions of factor VIII, which achieves normal factor VIII blood levels for only a few hours at a time. The product being developed by the HemAcure consortium will seek to provide constant delivery of Factor VIII to normalize blood levels in an effort to significantly improve the quality of life of patients suffering from hemophilia A.

The product being developed by the HemAcure consortium is expected to be highly disruptive to the current standard of care treatments for hemophilia A. The therapeutic goal of the product is to use the patient’s own cells corrected for the factor VIII gene. These cells placed in the implanted Cell Pouch will release factor VIII on a continual basis at a rate that would be expected to significantly reduce disease-associated hemorrhaging and joint damage. The constant delivery of factor VIII is also expected to reduce or eliminate the need for multiple weekly infusions which is the current standard of care using plasma-derived or recombinant, genetically engineered factor VIII for the prophylactic treatment of hemophilia A.

“The therapeutic potential to have a constant release of factor VIII from a hemophilia A patient’s own genetically corrected cells placed within the implanted Cell Pouch would be a very significant advance in the treatment of hemophilia A,” remarked Dr. David Lillicrap, MD, FRCPC Professor Department of Pathology and Molecular Medicine Queens University, Canada Research Chair in Molecular Hemostasis and member of the HemAcure Scientific Advisory Board. “Sernova’s Cell Pouch with its vascularized tissue lined chambers for therapeutic cells, which has already been proven for islet safety and survival in human clinical assessment of diabetes, is an ideal, fully scalable first-in-class medical device suitable for the potential treatment of hemophilia,” added Dr. Lillicrap.

“It has been exciting working together with the highly skilled team of experts in the HemAcure consortium in hemophilia and cell therapy. The scientific strength of this consortium was evident from the inception of the idea through the development and awarding of the grant to the stimulating kick off meeting,” said Delfina Siroen, Sr. Director of Sernova’s Research and Development team. “In a very short time, Sernova’s hemophilia program has achieved great strides and the addition of this European grant and team will ensure the best possible outcome for this program to the clinic,” continued Ms. Siroen.

The preliminary preclinical proof of concept data used as a basis to support the foundation of the grant was generated in a collaborative agreement between Medicyte GmbH under the FP7 ReLiver project, grant agreement 304961 and Sernova Corp where cryopreserved cells with the ex vivo inserted corrected gene for factor VIII were successfully shipped and assessed in Sernova’s Cell Pouch at its headquarters in Canada. Regarding Sernova’s participation in the consortium, the review of the HemAcure grant proposal stated the following, “Participation of the third country partner (Sernova Corp) is essential for carrying out the (program). This is justified by the fact that the partner in question is the one who possesses the technology that will be the basis of the whole proposal, and which will perform all the in vivo studies. Sernova uses a scalable, contract manufactured, proprietary patented worldwide implantable medical device (Cell Pouch) transplanted with therapeutic cells. (It) has been in development for more than six years and has shown success in multiple small and large animal preclinical models and is now in a clinical trial for another therapeutic indication. This Cell Pouch device is the only such device that when implanted under the skin is proven to become incorporated with blood vessel enriched tissue-forming chambers for the placement of therapeutic cells. This implies that the Canadian partner (Sernova) is an essential partner for the success of this project.”

About Hemophilia A

People with Hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency is the most common form of Hemophilia and is a genetic disorder caused by missing or defective factor VIII, a blood clotting protein. Severe hemophilia occurs in about 60% of cases where the deficiency of Factor VIII is less than 1% of normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous change in the gene. According to the US Centers for Disease Control and Prevention hemophilia occurs in about 1 in 5,000 births. If the prolonged bleeding occurs in the brain of a person with hemophilia, it can be fatal. Prolonged bleeding in joints can cause inflammatory responses and permanent joint damage. Approximately 20,000 people in the United States and 10,000 in Europe have the moderate or severe form of hemophilia A, as well as approximately 2,500 in Canada. All races and ethnic groups are equally affected by hemophilia A. Though there is no cure for the disease, it can be controlled with regular infusions of recombinant clotting Factor VIII. Annual costs for the treatment of the disease for each patient may range from $60,000 to $260,000 US for a total cost of between $2-5B per year in North America and Europe.

About Horizon 2020 Programme

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly Euro 80 billion of funding available over seven years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The project is funded as part of societal challenges “personalizing health and care” in a specific call about innovative treatments and technologies. New therapies, such as gene or cell therapies, often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving therapeutic scale production and GMP standards at reasonable cost is often underestimated. The European Union aims to improve the development of advanced methods and devices for targeted and controlled delivery, and to bring these innovative treatments to the patient.

About HemAcure

HemAcure is the name of the consortium developing a product for hemophilia A. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 667421. The consortium members include the University Hospital Wurzburg (Coordinating Institute), Integrierte Management Systeme IMS e.K., Universita del Piemonte Orientale “Amedeo Avogadro,” Loughborough University, GABO:mi Gesellschaft für Ablauforganisation: milliarium mbH & Co. and Sernova Corp. The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy within Sernova’s prevascularized Cell Pouch to treat this bleeding disorder that should ultimately lead to improved quality of life of the patients.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our expectations of the potential benefits of the consortium and the Horizon 2020 hemophilia project, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
January 25, 201625 January, 2016

Sernova Announces Agreement with CCRM to Produce Specialized Cells for the Treatment of Diabetes

LONDON, ONTARIO – (Marketwire – January 26, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova’s licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.

“Sernova’s Cell Pouch System(TM) is a novel, preclinically validated and clinically tested platform for multiple types of therapeutic cells, including human islets,” said Dr. Philip Toleikis, President and CEO Sernova Corp. “Sernova’s CCRM partnership with CCRM’s expertise in developing production processes for cellular therapies is an important step in Sernova’s plan to commercialize an unlimited supply of glucose responsive, insulin producing cells for the Cell Pouch System. Sernova continues to seek out and evaluate optimal unlimited cell sources both internally developed and through corporate partnerships involving stem cell derived, and xenogeneic cell sources. Our manufacturing partnership with CCRM will provide the ability for the scale up production required to ensure successful commercialization of Sernova’s cellular therapies for diabetes,” added Dr. Philip Toleikis.

CCRM is a unique not-for-profit group that is solely focused on developing and commercializing cell therapy and regenerative medicine technologies. Sernova is a member of CCRM’s industry consortium, a group of nearly 50 companies formed to address bottlenecks in cell therapy and regenerative medicine product pipelines by enabling industry to engage with CCRM’s broad network of researchers and institutions. Industry consortium members represent key sectors in regenerative medicine – therapeutics, devices, reagents and cells as tools – and tremendous industry experience.

"As a member of CCRM’s industry consortium, Sernova is a valued partner in our quest to develop global breakthroughs in regenerative medicine,” remarked Michael May, President and CEO of CCRM. “Commercializing a regenerative medicine therapy for diabetes – the goal for Sernova and CCRM – has the potential to disrupt and transform current standard of treatment. We are excited about the timing of this partnership,” added Dr. May, “as it is our expectation that projects like this become candidates for the new advanced manufacturing initiative that we announced during a visit by Prime Minister Trudeau in mid-January.”

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System and our cell technologies, and manufacturing capabilities of CCRM are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
February 04, 20164 February, 2016

Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies

Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance

Source: Sernova Corp

February 5, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – February 5, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has received the ranking of fourth in the category of Life Sciences and Clean Technologies and has been selected as member of the “2016 TSX Venture 50” Companies. This is a prestigious group of top market performers from among the 1,791 companies listed on the Toronto Venture Exchange as of December 31, 2015.
"We are honoured to be distinguished by the TSX from amongst all TSX Venture Companies and are appreciative of our investors who have rewarded our progress as acknowledged through the TSX Venture Exchange,” remarked Dr. Philip Toleikis, President and CEO. “We congratulate our peer companies in this category who have shown superior results in key metrics of market performance such as market capitalization growth, share price appreciation and trading volume – with Sernova providing a return of 118% in market cap appreciation in 2015. The shares of these companies also enjoyed a liquid market, with a total of 3.0 billion shares traded over the course of 2015,” added Dr. Toleikis.

“Sernova’s ongoing development of its platform technologies for cell therapy, the advancement of it programs in diabetes and hemophilia, and its focus on forging mutually beneficial pharmaceutical collaborations will, we believe, make 2016 another rewarding year for our shareholders and investors,” stated Frank Holler, Sernova Chairman. “This TSX Venture recognition adds to our growing profile in the public markets and we are most appreciative of receiving this distinction," added Mr. Holler.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
July 11, 201611 July, 2016

Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes

$2.45 million USD awarded to advance Sernova’s Cell Pouch System(TM) (CPS) technologies in a US FDA Clinical Trial with Initiation Scheduled for the Second Half of 2016

Source: Sernova Corp
July 12, 2016, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – July 12, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today it has entered into a research funding agreement with JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research. The purpose of the funding is to advance human clinical trials of Sernova’s CPS technologies for treatment of hypoglycemia unawareness patients with severe type 1 diabetes. T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose.

JDRF will provide Sernova up to $2.45 million USD to support a clinical trial at a major transplantation center in the United States. The goal of the study is to provide patients with hypoglycemia unawareness a novel cell therapy treatment utilizing Sernova’s proprietary, highly vascularized, cell macroencapsulated implantable and scalable device to reduce or eliminate the need for injections of exogenous insulin.
“JDRF has previously provided funding to advance the development of Sernova’s technologies through a preclinical collaboration with Massachusetts General Hospital, and we are proud to continue our support as Sernova’s technologies progress into new safety and efficacy clinical trials,” said Derek Rapp, JDRF President and CEO. “JDRF is excited about this collaboration, which advances research in encapsulated cell therapies, and will continue to drive progress toward our mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications.”
“Sernova and JDRF are tightly aligned in our vision to see cell-based therapies developed to reduce disease burden and significantly increase the quality of life for people living with T1D,” remarked Dr. Philip Toleikis, Sernova’s President and CEO. “We see our work with JDRF on this important clinical trial as an exciting opportunity to more rapidly advance Sernova’s therapies to treat people with diabetes and address many of the shortcomings and challenges of current insulin therapy.”
“Sernova’s progression to human clinical trials is an incredible accomplishment in the global diabetes research agenda,” said Dave Prowten, President and CEO of JDRF Canada. “I am particularly proud of this trial being a part of the JDRF portfolio because it supports advancements of the best and brightest research minds in Canada at Sernova. Also, this is a shining example of the international collaboration fostered by projects funded by JDRF. Working together with our global partners, we can accelerate this type of transformative research and ensure it becomes available for the T1D community.”

To date, there is no cure for T1D, and people living with the disease are dependent on insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova
Sernova Corp is a clinical stage regenerative medicine Company developing highly disruptive medical technologies to improve the treatment and quality of life of people with chronic debilitating metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device which forms highly vascularized chambers, ideal for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required to treat disease. For more information, please visit Sernova.com or follow us on Twitter: @SernovaCorp

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Sernova Receives US FDA IND Allowance to Initiate a US Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes

Source: Sernova Corp
December 11, 2017, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – Monday December 11, 2017) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing regenerative medicine technologies for the long-term treatment of diseases including diabetes and hemophilia, is pleased to announce it has received US Food and Drug Administration (FDA) notice of allowance for its IND for a new human clinical trial with the Cell Pouch System (TM) (CPS) in the United States. The Company will host a conference call for shareholders with Dr. Philip Toleikis, President and CEO on Monday, December 11th at 10:00am Eastern Standard Time to discuss the trial.

Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for treatment of type 1 diabetes (T1D) in individuals with hypoglycemia unawareness. The trial is a Phase I/II prospective single arm study of islets transplanted into the subcutaneously implanted Cell Pouch. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch and the secondary objective is to assess efficacy through a series of defined measures.

JDRF has previously committed to provide Sernova up to $2.45 million USD to support the clinical trial.

“Hypoglycemia unawareness is a serious consequence of type 1 diabetes,” said Derek Rapp, President & CEO, JDRF International. “We are excited to see progress in this and other potentially life-saving JDRF-funded research, which could help prevent people with hypoglycemia unawareness from experiencing dangerous lows, as we strive to achieve our vision of a world without T1D.”

“We are extremely enthusiastic about the promise of Sernova’s regenerative medicine platform to provide a new therapeutic option for diabetes patients with hypoglycemia unawareness. We believe Sernova’s multiple advancing cell based therapies have the potential to deliver significant improvement in the quality of life of patients suffering from diabetes and other debilitating diseases,” said Dr. Philip Toleikis, Sernova’s president & CEO.

About the Trial

The study is a Phase I/II single site, single arm, Company sponsored trial. Following approval by the Institutional Review Board, patients with hypoglycemia unawareness will be enrolled into the study under informed consent. Patients will then be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue development, a dose of purified islets under strict release criteria will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for approximately six months. At this point a decision will be made whether to transplant a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year.

“Sernova’s FDA clearance to commence human clinical trials in the United States is an exciting step forward in diabetes research, initially focused to reduce the risk of hypoglycemia unawareness, a complication in which a patient is unaware of a deep drop in blood sugar that can have life threatening consequences,” said Dave Prowten, President and CEO of JDRF Canada. “This is also an example of the international collaboration fostered by JDRF-funded projects to accelerate transformative research to benefit the T1D community,” added Mr. Prowten.

About Sernova’s Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed upon implantation to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin producing cells in humans.

About Diabetes

T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

Conference Call Details

To participate in this live conference call, please dial + 1-877-858-5743 prior to the scheduled conference call time. International callers should dial +1-858-609-8959. The conference participant pass code is 355 040. Following the conference call a recording will be available at www.sernova.com

About Sernova Corp

Sernova Corp is developing disruptive regenerative medical technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Continuous Glucose Monitoring System (CGM) to provide sensitive tracking of key efficacy measures in patients at important time points throughout the study

Source: Sernova Corp
February 22, 2018, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – February 22, 2018) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases including diabetes and hemophilia, is pleased to announce continuous glucose monitoring systems (CGM (Medtronic Minimed, Northridge, CA)) will be provided to patients in Sernova’s US regenerative medicine clinical trial of its Cell Pouch(TM). CGM will be used to track the function of the transplanted cells in the measurement of key efficacy measures at multiple time points following transplantation of the therapeutic cells into the Cell Pouch.

Glucose variability and hypoglycemia duration can be determined using CGM. CGM involves the subcutaneous placement of a glucose sensor connected to a pager-sized monitoring device that stores glucose data over a 6-day period. Data from each period will be analyzed for mean glucose concentration, mean glucose variability, number and duration of hyper- and hypo- glycemic episodes, and total duration of hypoglycemia.

“We believe continuous glucose monitoring of patients may be an important and sensitive method to closely track the function of the transplanted therapeutic cells within the Cell Pouch,” said Dr. Philip Toleikis, Sernova’s President and CEO. “We are pleased with our collaborators in this study who have shown the foresight to support Type 1 diabetes patients seeking treatment via next-generation regenerative medicine technologies.”

Sernova has recently received US Food and Drug Administration (FDA) notice of allowance for its IND for a new human clinical trial with the Cell Pouch System (CPS) in the United States. Sernova is taking final steps to begin enrollment of patients in the new clinical trial under this US IND to investigate the Cell Pouch for treatment of type 1 diabetes (T1D) in individuals with hypoglycemia unawareness. The trial is a Phase I/II prospective single arm study of islets transplanted into the subcutaneously implanted Cell Pouch. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch and the secondary objective is to assess efficacy through a series of defined measures.

About the Trial
The study is a Phase I/II single site, single arm, Company sponsored trial. Following approval by the Institutional Review Board, patients with hypoglycemia unawareness will be enrolled into the study under informed consent. Patients will then be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue development, a dose of purified islets under strict release criteria will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for approximately six months. At this point a decision will be made whether to transplant a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. CGM is planned to provide a sensitive and accurate tracking method to follow important efficacy measures at various time points throughout the study.

About Sernova’s Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed upon implantation to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models with diabetes and has been proven to provide a biologically compatible environment for insulin producing cells in humans.

About Diabetes
T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Corp
Sernova Corp is developing disruptive regenerative medical technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
May 07, 20187 May, 2018

Leading Surgeon and Researcher in Islet Transplantation at the University of Chicago to
act as Clinical Trial Principal Investigator. Study to focus on severely diabetic patients
with hypoglycemia unawareness

Source: Sernova Corp

May 8, 2018, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire May 8, 2018) – Sernova Corp. (TSX-V: SVA)
(OTCQB: SEOVF) (FSE: PSH), announces Dr. Piotr Witkowski, M.D., Ph.D., a leading
expert in type 1 diabetes (T1D) and islet transplantation, as the Clinical Trial Principal
Investigator for Sernova’s new clinical study. Dr Witkowski, at the University of Chicago
site, will work closely with Sernova’s team to conduct the clinical and regulatory aspects
of the Cell Pouch trial.

Dr. Witkowski is a widely published diabetes researcher and respected surgeon with a
longstanding record of success in both basic science and clinical research pertaining to
islet cell and abdominal organ transplantation. Among other accomplishments, he was
instrumental in developing an optimized islet isolation technique that greatly improved
success in clinical transplants. Under Dr. Witkowski's leadership, multidisciplinary
research teams at the University of Chicago are currently conducting several studies
designed to improve the quality and outcomes of islet cell transplantation in patients with
T1D.

“Sernova’s achievement to commence US human clinical trials is a key step to
improving the therapeutic treatment for people living with diabetes. This Cell Pouch
safety and efficacy trial aims to reduce the risk of hypoglycemia unawareness, a
complication in which a patient is unable to recognize and control impending
hypoglycemia resulting in a drop in blood sugar that can have life threatening
consequences,” said Dr. Witkowski. “Our experienced diabetes treatment team at the
University of Chicago sees the potential of this transformative therapy to benefit and
substantially improve the care of T1D.”

“Improving the quality of life and outcomes of people with diabetes are Sernova’s main
priorities, and we are grateful to have the opportunity to work with Dr. Witkowski and his
expert team at the University of Chicago, a team known for outstanding diabetes
research and patient care,” stated Dr. Philip Toleikis, Sernova’s President & CEO.

The study is a Phase I/II, non-randomized, unblinded, single-arm, company sponsored
trial. Under the clinical leadership of Dr. Witkowski, University of Chicago Medicine,
patients with hypoglycemia unawareness will be enrolled in the study under informed
consent. Patients then will be implanted with the Cell Pouch including sentinel devices.
Following vascularized tissue development in the Cell Pouch, an initial dose of purified
islets under strict release criteria will be transplanted into the Cell Pouch and patients
followed for safety and efficacy measures for approximately six months. At this point a
decision will be made with regards to the transplant of a second islet dose with
subsequent safety and efficacy follow up. Patients will then be further followed for one
year, with interim patient results released at periodic intervals consistent with an open
label study.

About Dr. Witkowski
Piotr Witkowski M.D. Ph.D. is an Associate Professor of Surgery and a transplant
surgeon at the University of Chicago Medicine. He has been involved in islet
transplantation research for the past 17 years, initially at Columbia University in New
York City and then as a Director of the Pancreatic Islet Transplantation Program at the
University of Chicago Medicine. For the last nine years, Dr. Witkowski has been
conducting multiple clinical studies in intraportal islet allotransplantation in patients with
brittle type diabetes as well as islet autotransplantation in patients with chronic
pancreatitis. Recently, he accomplished a phase 3 clinical trial and is currently preparing
application to the FDA for islet graft as a biological product, which is pivotal to enable
islet transplantation to become available to patients as a standard of care procedure.
Being aware of shortcomings of intrahepatic islet transplantation, Dr Witkowski has been
working on optimization of the subcutaneous location for improved islet engraftment. He
has proven the concept that this pre-vascularized site enhances islet survival in a
preclinical diabetes model.

About Sernova Corp
Sernova Corp is developing disruptive regenerative medical technologies using a
medical device (Cell Pouch) and immune protected therapeutic cells to improve the
treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated
through replacement of proteins or hormones missing or in short supply within the body.
For more information, please visit www.sernova.com

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are
statements that are not historical facts and are generally, but not always, identified by
the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”,
“potential” and similar expressions, or that events or conditions “will”, “would”, “may”,
“could” or “should” occur. Although Sernova believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions, such statements are
not guarantees of future performance and actual results may differ materially from those
in forward looking statements. Forward-looking statements, are based on the beliefs,
estimates and opinions of Sernova’s management on the date such statements were
made, which include our belief about the conduct and outcome of clinical trials and that
Sernova will be able to raise additional capital to fund its clinical programs including its
US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new information, future
events or otherwise.

The University of Chicago Institutional Review Board (IRB) is a committee established to
review and approve research involving human subjects. The purpose of the IRB is to
ensure that all human subject research is conducted in accordance with all federal,
institutional, and ethical guidelines. The primary goal of an IRB is to safeguard the rights,
safety and welfare of participants in research studies.

"The approval of our clinical protocol by the University of Chicago IRB represents a
significant milestone enabling the company to expand the clinical testing of our Cell
Pouch System to the US. Patient selection and enrollment can now proceed," said Dr.
Philip Toleikis, Sernova President and CEO.

The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-
sponsored trial, where diabetic subjects with hypoglycemia unawareness will be enrolled
into the study under informed consent. Subjects will then be implanted with Cell Pouches.
Following development of vascularized tissue chambers within the Cell Pouch, subjects
will then be stabilized on immunosuppression and a dose of purified islets under strict
release criteria will be transplanted into the Cell Pouch.

A sentinel pouch, also transplanted with islets, will be removed for an early assessment
of the islet transplant. Subjects will be followed for safety and efficacy measures for
approximately six months. At this point, a decision will be made with regards to the
transplant of a second islet dose with subsequent safety and efficacy follow up. Patients
will then be further followed for one year. The primary objective of the study is to
demonstrate safety and tolerability of islet transplantation into the Cell Pouch™. The
secondary objective is to assess efficacy through a series of defined measures.

About Sernova’s Cell Pouch™ Technologies
The Cell Pouch™ is a novel, proprietary, scalable, implantable macroencapsulation
device designed to prevent device fibrosis for the long-term survival and function of
therapeutic cells (donor, stem cell-derived cells and xenogeneic cells) which then release
proteins and/or hormones as required to treat disease. The device is designed upon
implantation to incorporate with tissue, forming highly vascularized tissue chambers for
the transplantation and function of therapeutic cells. The device with therapeutic cells has
been shown to provide long-term safety and efficacy in small and large animal models of
diabetes and has been proven to provide a biologically compatible environment for
insulin-producing cells in humans

About Diabetes
T1D is a life-threatening disease, affecting more than 3.3 million individuals in Canada
and US, in which the body's immune system mistakenly attacks and kills the pancreatic
cells that produce insulin a hormone that is essential for life because of its role to help the
body use glucose. The existing standard of care for patients with TID is suboptimal. To
date, there is no cure for T1D, and people living with the disease are dependent on
exogenous insulin therapy to help keep their blood-sugar levels from spiking too high,
which can lead to long-term complications such as kidney and heart diseases or an
acute, potentially deadly health crisis. Present-day insulin therapy is, however, an
imperfect treatment method that requires people with T1D to carefully monitor their
blood sugar throughout the day and take multiple, calculated doses of insulin based on
food intake, exercise, stress, illness and other factors. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of
people with T1D achieve their long-term blood glucose targets, placing them at risk for
T1D-related health complications.

About Sernova Corp
Sernova Corp is developing disruptive regenerative medical technologies using a
medical device and immune protected therapeutic cells to improve the treatment and
quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases. For more
information, please visit www.sernova.com

Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are
statements that are not historical facts and are generally, but not always, identified by
the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”,
“potential” and similar expressions, or that events or conditions “will”, “would”, “may”,
“could” or “should” occur. Although Sernova believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions, such statements are
not guarantees of future performance and actual results may differ materially from those
in forward looking statements. Forward-looking statements, are based on the beliefs,
estimates and opinions of Sernova’s management on the date such statements were
made, which include our belief about the conduct and outcome of clinical trials and that
Sernova will be able to raise additional capital to fund its clinical programs including its
planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to
update or revise any forward-looking statements whether as a result of new information,
future events or otherwise.

Share the news Partagez les nouvelles

Press ReleaseCommuniqué de presse
-
July 04, 20184 July, 2018

Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes

Sernova’s initial clinical evaluation of the
prevascularized Cell Pouch (TM) demonstrated
biocompatibility and safety of the Cell Pouch as well
as viability and vascularization of its
transplanted insulin-producing islets, a first in world
achievement in a prevascularized
implantable medical device.

“This first-in-human work helped frame the design
of Sernova’s new Phase I/II clinical
protocol. Our clinical team at the University of
Chicago is excited to initiate this trial of
Sernova’s transformative technology,” said
principal investigator, Dr. Piotr Witkowski,
M.D., Ph.D.

“To support the clinical study’s timely execution
under the highest quality standards,
Sernova and CTI (Clinical Trial and Consulting), a
well-respected clinical research
organization with deep experience in the
regenerative medicine field, are working
closely with Dr. Witkowski’s team,” said Dr. Philip
Toleikis, Sernova’s President and
CEO.

The study is a Phase I/II, non-randomized, open
label, single-arm, company-sponsored
trial. Under the clinical leadership of Dr. Witkowski,
University of Chicago Medicine,
subjects with hypoglycemia unawareness enrolled
in the study under informed consent
will be implanted with the Cell Pouch. Following
vascularized tissue development in the
Cell Pouch, an initial dose of purified islets under
strict release criteria will be
transplanted into the Cell Pouch.

A sentinel pouch, also transplanted with islets, will
be removed for an early assessment
of the islet transplant. Subjects will be followed for
safety and efficacy measures for
approximately six months. At this point, a decision
will be made with regards to the
transplant of a second islet dose with subsequent
safety and efficacy follow up. Subjects
will then be further followed for one year, with
interim participants results released at
periodic intervals consistent with an open-label
study.

About Sernova’s Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable,
implantable prevascularized
macroencapsulation device for the long-term
survival and function of therapeutic cells
(donor, stem cell derived cells and xenogeneic cells)
which then release proteins and/or
hormones as required to treat disease. The device
is designed to eliminate concerns of
fibrosis upon implantation by incorporating with
tissue, forming highly vascularized
tissue chambers for the transplantation and function
of therapeutic cells. The device with
therapeutic cells has been shown to provide long-
term safety and efficacy in small and
large animal models of diabetes and has been
proven to provide a biologically
compatible environment for insulin-producing cells
in humans.

About Diabetes

Type1 Diabetes (T1D) is a life-threatening disease
in which the body's immune system
mistakenly attacks and kills the pancreatic cells that
produce insulin—a hormone that is
essential for life because of its role to help the body
use glucose. The existing standard of
care for patients with TID is suboptimal. To date,
there is no cure for T1D, and people
living with the disease are dependent on exogenous
insulin therapy to help keep their
blood-sugar levels from spiking too high, which can
lead to long-term complications such
as kidney and heart diseases or an acute,
potentially deadly health crisis. Present-day
insulin therapy is, however, an imperfect treatment
method that requires people with
T1D to carefully monitor their blood sugar
throughout the day and take multiple,
calculated doses of insulin based on food intake,
exercise, stress, illness and other
factors. A miscalculation or unexpected variable
leading to high or low blood sugar
episodes are daily threats, and only a third of
people with T1D achieve their long-term
blood glucose targets, placing them at risk for T1D-
related health complications.

About Sernova Corp

Sernova Corp is developing regenerative medicine
therapeutic technologies using an
implantable medical device and immune protected
therapeutic cells to improve the
treatment and quality of life of people with chronic
metabolic diseases such as insulin-
dependent diabetes, blood disorders including
hemophilia, and other diseases treated
through replacement of proteins or hormones
missing or in short supply within the body.
For more information, please visit
www.sernova.com

This release may contain forward-looking
statements. Forward-looking statements are
statements that are not historical facts and are
generally, but not always, identified by
the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”,
“potential” and similar expressions, or that events
or conditions “will”, “would”, “may”,
“could” or “should” occur. Although Sernova
believes the expectations expressed in such
forward-looking statements are based on
reasonable assumptions, such statements are
not guarantees of future performance and actual
results may differ materially from those
in forward looking statements. Forward-looking
statements, are based on the beliefs,
estimates and opinions of Sernova’s management
on the date such statements were
made, which include our belief about the conduct
and outcome of clinical trials and that
Sernova will be able to raise additional capital to
fund its clinical programs including its
planned US clinical trial. Sernova expressly
disclaims any intention or obligation to
update or revise any forward-looking statements
whether as a result of new information,
future events or otherwise.

The therapeutic significance of this work supports the HemAcure Consortium’s concept that Factor VIII
genetically corrected human cells from a blood sample of patients with Hemophilia A transplanted into the Cell
Pouch can improve blood clotting.

“I am impressed with the achievements of this International Consortium within the limited time allowed. The
technical teams worked closely together to complete this work in developing a first-in-world ex vivo gene
therapy approach in an implanted vascularized medical device for the treatment of Hemophilia A.” said Dr.
David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University,
member of the Medical Advisory Board of the World Federation of Hemophilia, and HemAcure Scientific
Advisory Board member.

A summary of the Consortium’s achievements are as follows:

• In blood donated from patients with Hemophilia A, endothelial outgrowth cells to be corrected for the
Factor VIII gene were isolated and grown successfully in a specialized Good Manufacturing Process (cGMP)
compliant medium developed by the Consortium.

• Using a human Factor VIII gene insertion technique, the cells were corrected and confirmed to produce
Factor VIII.

• A preliminary experiment showed these cells could release Factor VIII in the blood over time and improve
blood clotting in an animal model of Hemophilia A, in preparation for transplant into the Cell Pouch.

• The corrected cells were proven to be successfully replicated through a production scale-up process.
Following amplification, these cells maintained their normal healthy behavior in producing Factor VIII.
Additional safety metrics were achieved using established tests.

• The cells were then cryopreserved and shipped from the European partners to Sernova in North America
where they were shown to remain healthy through quality control testing in preparation for transplantation.

• The Cell Pouch, manufactured under cGMP, and following implantation in the Hemophilia A animal model
showed development of vascularized chambers suitable to receive the corrected cells.

• Following transplantation into the Cell Pouch in a Hemophilia A animal model, the patient’s Factor VIII
corrected cells survived at three months (the duration of the study).

• Initial results showed Factor VIII released from the cells in the Cell Pouch was detected in blood and
notably, showed improved clotting when compared to the Hemophilia A animal control which did not receive
human corrected cells.

• The steps of the cell production process were documented towards development of the cGMP
manufacturing process for the corrected cells for future clinical use. An Instructions-for-Use document was
also developed for implantation of the cGMP Cell Pouch and transplantation of patient corrected Factor VIII
producing cells applicable for future human testing in patients with Hemophilia A.

Sernova’s President & CEO, Dr. Philip Toleikis added, “These series of breakthroughs demonstrate success in
correcting a Hemophilia A patient’s own cells to produce the missing Factor VIII protein and to improve blood
clotting in an animal model of Hemophilia A in preparation for future human clinical trials.”

Technical results will continue to be presented by HemAcure Consortium members at scientific conferences and
disseminated in scientific publications. Furthermore, steps are to complete cGMP manufacturing of the cells
using the tools and methods developed by the Consortium, optimize dosing of cells in the Cell Pouch to achieve
optimal therapeutic blood levels of Factor VIII, and conduct final formal studies in preparation for a first-in-
human clinical study.

HemAcure’s webinar in which the consortium expert leaders present an overview of the findings is now available
both on Sernova’s website at www.sernova.com and the HemAcure project website at www.hemacure.eu

About HemAcure

The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex
vivo prepared cell-based therapy to treat the bleeding disease, Hemophilia A (caused by a genetic deficiency in
clotting Factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European
Union's Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to
support the project. International consortium members include the University Hospital Wuerzburg
(Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del
Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United
Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario,
Canada. This project has received funding from the European Union’s Horizon 2020 Research and Innovation
Programme under grant agreement No 667421. The Consortium has been working together to provide sets of
design and manufacturing protocols, based on current European GMP regulations to prepare an Investigational
Medicinal Product Dossier (IMPD) for an Investigational Medicinal Product (IMP), composed of therapeutic cells
and an implantable medical device (Sernova’s Cell Pouch). For more information, visit www.hemacure.eu

About Hemophilia A

People with Hemophilia A have prolonged abnormal bleeding as a result of trauma. Hemophilia A is the most
common form of Hemophilia and is a genetic disorder caused by missing or defective FVIII, a blood clotting
protein. Severe Hemophilia A occurs in about 60% of cases where the deficiency of FVIII is less than 1% of
normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused
by a spontaneous change in the gene. According to the US Centers for Disease Control and Prevention,
Hemophilia A occurs in about 1 in 5,000 births. Prolonged bleeding, in areas such as the brain, of a person with
Hemophilia A, can be fatal. Prolonged bleeding in joints can cause inflammatory responses and permanent joint
damage. Approximately 20,000 people in the United States, 2,500 in Canada and 10,000 in Europe have
moderate to severe forms of Hemophilia A. Though there is no cure for the disease, Hemophilia A can be
controlled with regular infusions of recombinant clotting FVIII. Annual worldwide costs for the treatment of the
disease for each patient may range from $60,000 to $260,000 US for a total cost of approximately $15B per
year.

About Horizon 2020 Programme

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding
available over seven years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by
taking great ideas from the lab to the market. The project is funded as part of societal challenges “personalizing
health and care” in a specific call about innovative treatments and technologies. New therapies, such as gene or
cell therapies, often require technological innovation in the form of development of specific component tools
and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the
therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving
therapeutic scale production and cGMP standards at reasonable cost is often underestimated. The European
Union aims to improve the development of advanced methods and devices for targeted and controlled delivery,
and to bring these innovative treatments to the patient.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic
diseases such as insulin-dependent diabetes, blood disorders including Hemophilia A, and other diseases
treated through replacement of proteins or hormones missing or in short supply within the body. For more
information, please visit www.sernova.com

This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of the Hemophilia
A program. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or otherwise.

HemAcure Webinar: https://youtu.be/ihyHefvJ8cQ

Dr. Philip M. Toleikis

President, CEOPrésident, Chef de la Direction

BA, MSc, PhD

Dr. Toleikis is currently President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development - Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. M. Toleikis est actuellement président et chef de la direction de Sernova Corp depuis avril 2009. De 2006 à 2009, le Dr Toleikis a consulté plusieurs sociétés pharmaceutiques, produits combinés et produits à dispositifs multiples. De 1996 à 2006, il a occupé plusieurs postes chez Angiotech Pharmaceuticals, Inc., dont celui de vice-président, Recherche et développement - Pharmacologie et dépistage de drogues. Il a constitué une équipe de développement de produits composée de plus de 50 scientifiques et a collaboré à plusieurs

Dr. Toleikis is the author of multiple issued patents, over 110 patent applications, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont. M. Toleikis est l'auteur de plusieurs brevets délivrés, de plus de 110 demandes de brevet et de nombreuses publications scientifiques sur la transplantation, les maladies métaboliques, cardiovasculaires, oncologiques et auto-immunes. Il a obtenu son doctorat en médecine, pharmacologie et thérapeutique de l'Université de la Colombie-Britannique, son M.Sc. à l'Université du Michigan et B.A. à l'Université du Vermont.

Among a number of volunteer activities he is a speaker at JDRF events, and a community member of UHP school council in London, Ontario.Parmi plusieurs activités de bénévolat, il est conférencier lors des événements de la FRDJ et membre communautaire du conseil scolaire UHP de London, en Ontario.

From 2002 through 2005 Mr. Bacha served as President and Founding CEO of Inimex Pharmaceuticals, where he was responsible for establishing the company’s research &development team and leading venture capital financing and grant funding efforts which raised more than $35 million to support the company’s research programs.De 2002 à 2005, M. Bacha a été président et PDG fondateur d'Inimex Pharmaceuticals, où il était responsable de la mise en place de l'équipe de recherche et développement et des efforts de financement de capital-risque et de financement. .

Since 2005 until founding Del Mar Pharmaceuticals, Mr. Bacha has consulted with a number of life sciences companies and served as Executive Vice President, Corporate Affairs and Chief Operating Officer of Clera Inc. He holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego.Depuis 2005 et jusqu'à la fondation de Del Mar Pharmaceuticals, M. Bacha a consulté de nombreuses entreprises du secteur des sciences de la vie et a été vice-président exécutif, affaires générales et chef de l'exploitation de Clera Inc. Il est titulaire d'un MBA de la Goizueta Business School un diplôme en bio-physique de l'Université de Californie à San Diego.

Mr. Parsons has a broad background in the life sciences industry across therapeutics, diagnostics and device companies and over 25 years of financial management experience. Mr. Parsons has secured over $300 million of various forms of financing during his career and has advised and assisted on over $200 million of product licensing deals. M. Parsons a une vaste expérience dans l’industrie des sciences de la vie dans le secteur des produits thérapeutiques, des diagnostics et des appareils, et plus de 25 années d’expérience en gestion financière. M. Parsons a obtenu plus de 300 millions de dollars de diverses formes de financement au cours de sa carrière et a conseillé et aidé plus de 200 millions de dollars en contrats de licence de produits.

Mr. Parsons also serves on the board of directors of DiaMedica Therapeutics Inc. He has extensive experience in public company governance and compliance. He has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant.M. Parsons siège également au conseil d'administration de DiaMedica Therapeutics Inc. Il possède une vaste expérience en matière de gouvernance et de conformité des sociétés ouvertes. Il est titulaire d'une maîtrise en comptabilité de l'Université de Waterloo et est comptable professionnel agréé et comptable agréé.

Mr. Weber earned a B.S. in biology from Bowling Green State University and an MBA from Nova University.M. Weber a obtenu un B.S. en biologie de la Bowling Green State University et un MBA de Nova University.

Mr. Holler was previously a Director of the British Columbia Biotechnology Association from 1992 to 1998, and in 2003 received the BC Biotech Award for Vision and Leadership. He holds an MBA and BA (Economics) from the University of British Columbia.M. Holler était auparavant directeur de la British Columbia Biotechnology Association de 1992 à 1998 et, en 2003, il a reçu le prix BC Biotech pour sa vision et son leadership. Il est titulaire d'un MBA et d'un baccalauréat en économie de l'Université de la Colombie-Britannique.

Privacy PolicyPolitique de confidentialité

Updated July 6, 2018

Please read this Policy carefully along with our Legal Notice that describes our Terms of Use for the Website.

By accessing www.sernova.com (the “Website”) you hereby agree with the practices described in this Privacy Policy (the “Policy”)

This Policy applies to all information gathered through the Website and/or any related marketing technique or events.

Information Collection

The information collected is limited to the information that you decide to share with us through the News Dispatch Service, when participating at event or activities or in the general course of business by expressing an interest in obtaining information about Sernova Corp. and our products, such as name, email, phone number, and similar contact information. This information is stored through MailChimp (please refer to MailChimp Privacy Policy at https://mailchimp.com/legal/privacy/).

Information Sharing

Sernova Corp. is the sole owner of any information collected on the Website. We do not sell, share or rent this information to others.

Traffic and Automatic Information Collection

Sernova Corp. maintains log files of the traffic on www.sernova.com. This information is not linked to any personal information that you have provided us. Logs are used to manage traffic, identify content accessed, and IT requirements. Information logged and automatically collected includes without being limited to IP addresses and browser types. This information does not reveal your specific identity.

Cookies

Cookies can be used to provide you with a more personalized experience. The Website may use cookies to make that experience more companionable when you return to the Website. You have the option at all time to decline the use of cookies. If you choose to do so, you may not be able to fully use all features of the Website. You can also delete cookie files at all time from your computer. Those cookies may include first-party cookies (such as the Google Analytics cookies).

Updates

This Policy is a living document and may be amended or updated from time to time without further notice. We encourage you to review the Policy periodically.